Incyte Corp. has identified tyrosine-protein kinase JAK2 (V617F mutant) inhibitors reported to be useful for the treatment of cancer, hypereosinophilic syndrome, systemic mastocytosis and essential thrombocythemia, among others.

Insilico Medicine Inc. has synthesized fibroblast growth factor receptor 2 (FGFR2) and/or FGFR3 inhibitors reported to be useful for the treatment of cancer.

Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

Molecure SA has signed an exclusive licensing agreement with Ocean Biomedical Inc. for the development and commercialization of a selective YKL-40 inhibitor program, including the lead molecule OAT-3912.

In a recent presentation, researchers from the Medical University of Lodz have aimed to investigate the therapeutic potential of simultaneously targeting axin and cannabinoid receptors (CBs) with KYA-1797K and WIN-55212-2 in colorectal cancer (CRC) cell lines SW480 and Caco-2.

In recent years, immune checkpoint inhibitors have had great success in the treatment of advanced cancers, but often, they are only effective in a minority of patients. Researchers from Weill Cornell Medicine have discovered that the activation of the pentose phosphate pathway (PPP) in combination with standard immune checkpoint inhibitors resulted in enhanced antitumor efficacy both in vitro and in vivo.

Shanghai Helioson Pharmaceutical Co. Ltd. has identified molecular glue degraders acting as DNA-binding protein Ikaros (IKZF1) and/or zinc finger protein Aiolos (IKZF3) degradation inducers reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.

Westlake Therapeutics (Hangzhou) Co. Ltd. and affiliated organizations have reported the design and preclinical characterization of novel erythrocytes conjugated to major histocompatibility complex (MHC) class I (MHC-I) protein, being developed for the treatment of cancer.